Drug Profile


Alternative Names: GED-aPC; LY458202

Latest Information Update: 15 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Anticoagulants; Antithrombotics
  • Mechanism of Action Protein C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Cardiogenic shock

Most Recent Events

  • 23 Nov 2010 Suspended - Phase-I for Cardiogenic shock in Canada (IV)
  • 25 Sep 2009 Cardiome is seeking inverstors and/or partners to fund the development of GED aPC \\
  • 24 Mar 2009 Phase-I development is ongoing in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top